

DAFTAR PUSTAKA

1. Li N, Zhang YH, Xiong XL, Li ZG, Jin XH, Wu YN. Study of the physicochemical properties of trimethoprim with β -cyclodextrin in solution. *J Pharm Biomed Anal.* 2005;38(2):370–4.
2. Li N, Zhang YH, Wu YN, Xiong XL, Zhang YH. Inclusion complex of trimethoprim with β -cyclodextrin. *J Pharm Biomed Anal.* 2005;39(3–4):824–9.
3. Zaini E, Sumirtapura YC, Halim A, Fitriani L, Soewandhi SN. Formation and characterization of sulfamethoxazole-trimethoprim cocrystal by milling process. *J Appl Pharm Sci.* 2017;7(12):169–73.
4. Manius GJ. Trimethoprim. *Anal Profiles Drug Subst Excipients.* 1978;7(C):445–75.
5. Christopher Vimalson D, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Techniques to enhance solubility of hydrophobic drugs: An overview. *Asian J Pharm.* 2016;10(2):S67–75.
6. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. *Pharmaceutics.* 2019;11(3):1–26.
7. Garnero C, Zoppi A, Genovese D, Longhi M. Studies on trimethoprim: Hydroxypropyl- β -cyclodextrin: Aggregate and complex formation. *Carbohydr Res [Internet].* 2010;345(17):2550–6. Available from: <http://dx.doi.org/10.1016/j.carres.2010.08.018>
8. Zaini E et al. Peningkatan Laju Pelarutan Trimetoprim Melalui Metode Ko-Kristalisasi Dengan', *Jurnal Farmasi Indonesia.*, *J Farm Indones.* 2011;5(4) pp(March 2014):205–12.
9. Putra OD, Furuishi T, Yonemochi E, Terada K, Uekusa H. Drug-Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs. *Cryst Growth Des.* 2016;16(7):3577–81.
10. Grothe E, Meekes H, Vlieg E, Ter Horst JH, De Gelder R. Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Cryst Growth Des.* 2016;16(6):3237–43.
11. Jones W, Motherwell WDS, Trask A V. Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement. 2006;31(November):875–9.
12. Sarma B, Chen J, Hsi HY, Myerson AS. Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals. *Korean J Chem Eng.* 2011;28(2):315–22.

13. Kumar S, Nanda A. Pharmaceutical cocrystals: An overview. *Indian J Pharm Sci.* 2017;79(6):858–71.
14. Yuliandra Y, Hutabarat LJ, Ardila R, Octavia MD, Zaini E. Enhancing solubility and antibacterial activity using multi-component crystals of trimethoprim and malic acid. *Pharm Educ.* 2021;21(2):296–304.
15. Brittain HG. Mandelic Acid. *Anal Profiles Drug Subst Excipients.* 2002;29(C):179–211.
16. Zhang SW, Harasimowicz MT, De Villiers MM, Yu L. Cocrystals of nicotinamide and (R)-mandelic acid in many ratios with anomalous formation properties. *J Am Chem Soc.* 2013;135(50):18981–9.
17. Leysens T. Innovative Chiral Resolution Using Enantiospecific Co-Crystallization in Solution. 2012;
18. Springuel G, Norberg B, Robeyns K, Wouters J, Leysens T. Advances in pharmaceutical Co-crystal screening: Effective Co-crystal screening through structural resemblance. *Cryst Growth Des.* 2012;12(1):475–84.
19. Fernandes RP, Carina A, Carvalho S De, Ekawa B, Luiz A, Carneiro S, et al. Synthesis and characterization of meloxicam eutectics with mandelic acid and saccharin for enhanced solubility. 2020;9045(May).
20. Raquel Á, Castiñeiras A, Frontera A, Garc I, Gil DM, Gonz JM, et al. Weak Interactions in Cocrystals of Isoniazid with Glycolic and Mandelic Acids. 2021;
21. Tumanova N, Payen R, Springuel G, Norberg B, Robeyns K, Le Duff C, et al. Cocrystallization out of the blue: DL-mandelic acid/ethyl-DL-mandelate cocrystal. *J Mol Struct.* 2017;1127:397–402.
22. PubChem. Trimethoprim [Internet]. 2004. [cited 2022 Mar 22]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Trimethoprim>.
23. Drugbank. Mandelic acid [Internet]. 2017 [cited 2022 Feb 10]. Available from: <https://go.drugbank.com/drugs/DB13218>
24. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. *Int J Pharm [Internet].* 2013;453(1):101–25.
25. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. *Acta Pharm Sin B [Internet].* 2021;11(8):2537–64. Available from: <https://doi.org/10.1016/j.apsb.2021.03.030>
26. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. *Int J Pharm [Internet].* 2011;419(1–2):1–11. Available from: <http://dx.doi.org/10.1016/j.ijpharm.2011.07.037>

27. PubChem. Mandelic Acid [Internet]. 2022. [cited 2022 Aug 10]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Mandelic-acid>
28. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev* [Internet]. 2017;117:25–46. Available from: <https://doi.org/10.1016/j.addr.2017.03.002>
29. Jianbing Tan JL and LR. A Review of Pharmaceutical Nano-Cocrystals : A Novel Strategy Soluble Drugs. *Crystals*. 2021;11(463):1–14.
30. Serajuddin ATM. Salt formation to improve drug solubility. *Adv Drug Deliv Rev*. 2007;59(7):603–16.
31. Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. *Adv Drug Deliv Rev* [Internet]. 2017;117:86–110.
32. Karagianni A, Malamataris M, Kachrimanis K. Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. *Pharmaceutics*. 2018;10(1):1–30.
33. Aitipamula S, Chow PS, Tan RBH. Solvates of the antifungal drug griseofulvin: Structural, thermochemical and conformational analysis. *Acta Crystallogr Sect B Struct Sci Cryst Eng Mater*. 2014;70(1):54–62.
34. Othman A, Evans JSO, Evans IR, Harris RK, Hodgkinson P. Structural Study of Polymorphs and Solvates of Finasteride. *J Pharm Sci*. 2007;96(7):1380–97.
35. Henry R, Zhang GGZ. Crystallographic Characterization of Several Erythromycin A Solvates: The Environment of the Solvent Molecules in the Crystal Lattice. *J Pharm Sci*. 2006;96(5):1251–7.
36. Xu W, Gong N, Yang S, Zhang N, He L, Du G, et al. Isostructurality among Solvates of Cabazitaxel: X-ray Structures and New Solvates Preparation. *J Pharm Sci*. 2015;104(4):1256–62.
37. Cavallari C, Santos BPA, Fini A. Olanzapine solvates. *J Pharm Sci*. 2013;102(11):4046–56.
38. Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, et al. Polymorphs, salts, and cocrystals: What's in a name? *Cryst Growth Des*. 2012;12(5):2147–52.
39. Izutsu KI, Koide T, Takata N, Ikeda Y, Ono M, Inoue M, et al. Characterization and quality control of pharmaceutical cocrystals. *Chem Pharm Bull*. 2016;64(10):1421–30.
40. Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: Along the path to improved medicines. *Chem Commun* [Internet]. 2016;52(4):640–55.

41. Mohamed S, Tocher DA, Vickers M, Karamertzanis PG, Price SL. Salt or cocrystal? A new series of crystal structures formed from simple pyridines and carboxylic acids. *Cryst Growth Des.* 2009;9(6):2881–9.
42. Pawar N, Saha A, Nandan N, Parambil J V. *Solution Cocrystallization : A Scalable Approach for Cocrystal Production.* 2021;
43. Gill P, Moghadam TT, Ranjbar B. Differential Scanning Calorimetry Techniques: Applications in Biology and Nanoscience. *J Biomol Tech.* 2010;21(4):167–93.
44. Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques. *Adv Drug Deliv Rev* [Internet]. 2017;117:111–46.
45. Noviza D, Zaini E. Identifikasi Interaksi Padat Campuran Parasetamol dan Ibuprofen dengan Metode Thermal. *J Farm Indones.* 2015;7(3).
46. Chieng N, Rades T, Aaltonen J. An overview of recent studies on the analysis of pharmaceutical polymorphs. *J Pharm Biomed Anal* [Internet]. 2011;55(4):618–44.
47. Giechaskiel B, Clairotte M. Fourier transform infrared (Ftir) spectroscopy for measurements of vehicle exhaust emissions: A review. *Appl Sci.* 2021;11(16).
48. Dachriyanus. *Analisis Struktur Senyawa Organik Secara Spektroskopi.* Padang: LPTIK Universitas Andalas; 2004.
49. Permatasari D, Ramadhani S, Sopyan I. Ko-Kristal: Teknik Pembuatan Ko-Kristal. *Farmaka* [Internet]. 2016;14(4):98–115. Available from: <http://jurnal.unpad.ac.id/farmaka/article/view/10461/5073>
50. Dhaval M, Makwana J, Sakariya E, Dudhat K. Drug Nanocrystals: A Comprehensive Review with Current Regulatory Guidelines. *Curr Drug Deliv.* 2020;17(6):470–82.
51. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm.* 2012;2012(100 mL):1–10.
52. Susanti M, Dachriyanus. *Kromatografi Cair Kinerja Tinggi.* Padang: LPTIK Universitas Andalas;
53. Sabir AM, Moloy M, Bhasin PS. Hplc Method Development and Validation: a Review. *Int Res J Pharm.* 2016;4(4):39–46.
54. Fadhila M, Umar S, Zaini E. Pembentukan Kokristal Asam Usnat – N-Methyl-DGlucamine dengan Metode Penguapan Pelarut dan Pengaruhnya terhadap Penurunan Interleukin-8 pada Tikus Inflamasi. *J Sains Farm Klin.* 2020;7(1):23.
55. Ilham NM. Identifikasi Interaksi Padatan pada Sistem Biner Asam Usnat-

Nikotinamida. Universitas Andalas; 2016.

56. Umar S, Putri Bandaro N, Anggraini D, Zaini E. Multicomponent Crystal of Fenofibric Acid-Saccharin: Characterization and Antihyperlipidemic Effectiveness. *Adv Heal Sci Res.* 2021;40(Iccscp):104–9.
57. Indonesia KKR. *Farmakope Indonesia Edisi VI.* Jakarta: Kementerian Kesehatan RI; 2020.
58. Umar S, Farnandi R, Salsabila H, Zaini E. Multicomponent Crystal of Trimethoprim and Citric Acid : Solid State Characterization and Dissolution Rate Studies. 2022;10:141–5.
59. Yadav A V., Shete AS, Dabke AP, Kulkarni P V., Sakhare SS. Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients. *Indian J Pharm Sci.* 2009;71(4):359–70.
60. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Sci Pharm.* 2020;88(2).
61. Wicaksono Y, Setyawan D, Siswandono. Formation of ketoprofen-malonic acid cocrystal by solvent evaporation method. *Indones J Chem.* 2017;17(2):161–6.
62. Bolla G, Sanphui P, Nangia A. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. *Cryst Growth Des.* 2013;13(5):1988–2003.
63. Mannava MKC, Gunnam A, Lodagekar A, Shastri NR, Nangia AK, Solomon KA. Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation. *CrystEngComm.* 2021;23(1):227–37.
64. Variankaval N, McNevin M, Shultz S, Trzaska S. High-Throughput Screening to Enable Salt and Polymorph Screening, Chemical Purification, and Chiral Resolution [Internet]. Vol. 9, *Comprehensive Organic Synthesis: Second Edition.* Elsevier Ltd.; 2014. 207–233 p. Available from: <http://dx.doi.org/10.1016/B978-0-08-097742-3.00922-8>
65. Nasa. Frandsen, Athela F. (Ksc-Bad00) Gs-07. 2016;3(321).
66. Ravisankar P, Naga Navya C, Pravallika D, Sri DN. A review on step-by-step analytical method validation. *IOSR J Pharm.* 2015;5(10):2250–3013.
67. Nugraheni B, Nafi'ah N, Anggoro B. Validasi Metode Analisis Dan Penurunan Kadar Infus Ciprofloksasin Yang Dipengaruhi Reaksi Oksidasi Menggunakan Hplc. *J Ilm Manuntung.* 2017;2(2):218.
68. United Nations Office on Drugs and Crime. A commitment to quality and continuous improvement. *Unodc.* 2009. 2–76 p.
69. Harmita. Petunjuk Pelaksanaan Validasi dan Cara Penggunaannya. *Majalah Ilmu Kefarmasian.* 2004;1(3):117.

70. Guy RC. International Conference on Harmonisation. *Encycl Toxicol* Third Ed. 2014;2(June 1995):1070–2.

